Component

Calcium fructoborate

Calcium fructoborate. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The pilot reported improved CRP and other measured inflammatory markers with calcium fructoborate compared with placebo over about two weeks.

    Calcium fructoborate → Serum C-reactive protein concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/boron-research/21607703.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "791318eaf72d7d13719549d6c655fa4023ebe6b5582776b785db1d403456a35d", "start_char": 0, "end_char": 1236, "text_sha256": "791318eaf72d7d13719549d6c655fa4023ebe6b5582776b785db1d403456a35d"}
    experimental_model
    Randomized placebo-controlled double-blind pilot in knee osteoarthritis
    exposure
    Approximately 15 days calcium-fructoborate supplementation; 116 recruited, 72 started and 60 completed
    limitations
    Short pilot with attrition and biomarker outcomes; it does not establish cartilage repair, disease modification or equivalence of all boron compounds.
    nutrient_topic
    Boron research collection; topical membership is not evidence of a direct dietary effect. · Boron
    organism
    Human
    plain_language
    The trial reported changes in blood markers; it did not show that damaged joints were rebuilt.
    primary_references
    [boron-p21607703] A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis. (2011). https://pubmed.ncbi.nlm.nih.gov/21607703/ DOI: 10.1007/s12011-011-9083-0
    tissue_or_cell_type
    Blood inflammatory markers

    Boron: chemistry, nutrient interactions, low-intake studies and mechanistic uncertainties (2026-09-17) · lines 1054–1065

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized placebo-controlled double-blind pilot in knee osteoarthritis · source_derived_draft · unverified_draft

    ### boron-fructoborate-inflammatory-markers The pilot reported improved CRP and other measured inflammatory markers with calcium fructoborate compared with placebo over about two weeks. Condition category: normal nutrient_topic: Boron research collection; topical membership is not evidence of a direct dietary effect. plain_language: The trial reported changes in blood markers; it did not show that damaged joints were rebuilt. organism: Human tissue_or_cell_type: Blood inflammatory markers experimental_model: Randomized placebo-controlled double-blind pilot in knee osteoarthritis limitations: Short pilot with attrition and biomarker outcomes; it does not establish cartilage repair, disease modification or equivalence of all boron compounds. exposure: Approximately 15 days calcium-fructoborate supplementation; 116 recruited, 72 started and 60 completed evidence_span: {"source_cache": "artifacts/boron-research/21607703.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "791318eaf72d7d13719549d6c655fa4023ebe6b5582776b785db1d403456a35d", "start_char": 0, "end_char": 1236, "text_sha256": "791318eaf72d7d13719549d6c655fa4023ebe6b5582776b785db1d403456a35d"} [boron-p21607703] A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis. (2011). https://pubmed.ncbi.nlm.nih.gov/21607703/ DOI: 10.1007/s12011-011-9083-0
    Complete structured claim and evidence

  2. Calcium fructoborate reduced MPQ pain scores relative to placebo at day 7 (estimated difference −5.8, p=0.0009) and day 14 (−8.9, p<0.0001).

    Calcium fructoborate → Knee pain assessed by McGill Pain Questionnaire source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/boron-research/24940052.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be", "start_char": 0, "end_char": 1393, "text_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be"}
    experimental_model
    Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort
    exposure
    Calcium fructoborate 110 mg twice daily for 14 days; compound mass is not elemental boron dose
    limitations
    Short symptom trial. The 2021 correction (PMID 33564230, https://pubmed.ncbi.nlm.nih.gov/33564230/) disclosed FutureCeuticals funding/product supply, company employment and patent interests; the journal requested retrospective registration. Day-seven WOMAC p=0.06 was not conventionally significant despite broader wording in the original abstract. These are corrections/qualifications, not a new scientific conflict.
    nutrient_topic
    Boron research collection; topical membership is not evidence of a direct dietary effect. · Boron
    organism
    Human
    plain_language
    Participants reported less knee pain during this short trial.
    primary_references
    [boron-p24940052] Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. (2014). https://pubmed.ncbi.nlm.nih.gov/24940052/ DOI: 10.2147/cia.s64590
    tissue_or_cell_type
    Pain and WOMAC questionnaire outcomes

    Boron: chemistry, nutrient interactions, low-intake studies and mechanistic uncertainties (2026-09-17) · lines 1067–1078

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort · source_derived_draft · unverified_draft

    ### boron-fructoborate-knee-pain Calcium fructoborate reduced MPQ pain scores relative to placebo at day 7 (estimated difference −5.8, p=0.0009) and day 14 (−8.9, p<0.0001). Condition category: normal nutrient_topic: Boron research collection; topical membership is not evidence of a direct dietary effect. plain_language: Participants reported less knee pain during this short trial. organism: Human tissue_or_cell_type: Pain and WOMAC questionnaire outcomes experimental_model: Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort limitations: Short symptom trial. The 2021 correction (PMID 33564230, https://pubmed.ncbi.nlm.nih.gov/33564230/) disclosed FutureCeuticals funding/product supply, company employment and patent interests; the journal requested retrospective registration. Day-seven WOMAC p=0.06 was not conventionally significant despite broader wording in the original abstract. These are corrections/qualifications, not a new scientific conflict. exposure: Calcium fructoborate 110 mg twice daily for 14 days; compound mass is not elemental boron dose evidence_span: {"source_cache": "artifacts/boron-research/24940052.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be", "start_char": 0, "end_char": 1393, "text_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be"} [boron-p24940052] Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. (2014). https://pubmed.ncbi.nlm.nih.gov/24940052/ DOI: 10.2147/cia.s64590
    Complete structured claim and evidence

  3. The WOMAC treatment difference was −13.73 at day 14 (p<0.0001); the day-seven difference of −5.3 had p=0.06 and was not conventionally significant.

    Calcium fructoborate → Knee symptoms and function assessed by WOMAC source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/boron-research/24940052.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be", "start_char": 0, "end_char": 1393, "text_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be"}
    experimental_model
    Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort
    exposure
    Calcium fructoborate 110 mg twice daily for 14 days; compound mass is not elemental boron dose
    limitations
    Short symptom trial. The 2021 correction (PMID 33564230, https://pubmed.ncbi.nlm.nih.gov/33564230/) disclosed FutureCeuticals funding/product supply, company employment and patent interests; the journal requested retrospective registration. Day-seven WOMAC p=0.06 was not conventionally significant despite broader wording in the original abstract. These are corrections/qualifications, not a new scientific conflict.
    nutrient_topic
    Boron research collection; topical membership is not evidence of a direct dietary effect. · Boron
    organism
    Human
    plain_language
    The combined knee symptom/function score improved at two weeks; the one-week result was uncertain.
    primary_references
    [boron-p24940052] Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. (2014). https://pubmed.ncbi.nlm.nih.gov/24940052/ DOI: 10.2147/cia.s64590
    tissue_or_cell_type
    Pain and WOMAC questionnaire outcomes

    Boron: chemistry, nutrient interactions, low-intake studies and mechanistic uncertainties (2026-09-17) · lines 1080–1091

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort · source_derived_draft · unverified_draft

    ### boron-fructoborate-womac The WOMAC treatment difference was −13.73 at day 14 (p<0.0001); the day-seven difference of −5.3 had p=0.06 and was not conventionally significant. Condition category: normal nutrient_topic: Boron research collection; topical membership is not evidence of a direct dietary effect. plain_language: The combined knee symptom/function score improved at two weeks; the one-week result was uncertain. organism: Human tissue_or_cell_type: Pain and WOMAC questionnaire outcomes experimental_model: Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort limitations: Short symptom trial. The 2021 correction (PMID 33564230, https://pubmed.ncbi.nlm.nih.gov/33564230/) disclosed FutureCeuticals funding/product supply, company employment and patent interests; the journal requested retrospective registration. Day-seven WOMAC p=0.06 was not conventionally significant despite broader wording in the original abstract. These are corrections/qualifications, not a new scientific conflict. exposure: Calcium fructoborate 110 mg twice daily for 14 days; compound mass is not elemental boron dose evidence_span: {"source_cache": "artifacts/boron-research/24940052.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be", "start_char": 0, "end_char": 1393, "text_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be"} [boron-p24940052] Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. (2014). https://pubmed.ncbi.nlm.nih.gov/24940052/ DOI: 10.2147/cia.s64590
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards